|
Published by: Global Markets Direct
Published: Dec. 26, 2012 - 100 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Seasonal Allergic Rhinitis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Seasonal Allergic Rhinitis
- Seasonal Allergic Rhinitis Therapeutics under Development by Companies
- Seasonal Allergic Rhinitis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Seasonal Allergic Rhinitis Therapeutics – Products under Development by Companies
- Seasonal Allergic Rhinitis Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Seasonal Allergic Rhinitis Therapeutics Development
- Johnson & Johnson
- Bausch & Lomb Incorporated
- Shionogi & Co., Ltd.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Dainippon Sumitomo Pharma Co., Ltd.
- Novartis AG
- ALK-Abello A/S
- Mitsubishi Tanabe Pharma Corporation
- Teva Pharmaceutical Industries Limited
- Zeria Pharmaceutical Co Ltd
- Sun Pharmaceutical Industries Limited
- Capnia, Inc.
- VentiRx Pharmaceuticals, Inc.
- Adamis Pharmaceuticals Corporation
- Indigene Pharmaceuticals, Inc.
- Seasonal Allergic Rhinitis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- DSP-3025 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- bepotastine besylate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VAK-694 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Nasal Carbon Dioxide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- beclomethasone dipropionate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- QAX-576 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VTX-1463 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Z-207 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IG-RD-001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- S-555739 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VAK-694 + [Alutard Avanz SQ] - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- JNJ-38224342 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Modified Allergen Extract - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Allergen Extract - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Mometasone Furoate + Oxymetazoline - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RV-568 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SUN-1334 H - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SUN-1334 H - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- bepotastine besylate + steroid - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Alutard SQ - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TBS-6 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GSK-2445053 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- APC-3000 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GSK-2245035 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- S-555739 + Cetirizine HCl - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AVANZ Olive - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Seasonal Allergic Rhinitis Therapeutics – Drug Profile Updates
- Seasonal Allergic Rhinitis Therapeutics – Discontinued Products
- Seasonal Allergic Rhinitis Therapeutics - Dormant Products
- Seasonal Allergic Rhinitis – Product Development Milestones
- Featured News & Press Releases
- Nov 09, 2012: Teva Pharma's Qnasl Demonstrates Efficacy Profile In Pediatric Patients With Seasonal Allergic Rhinitis In Phase III Study
- Nov 06, 2012: Teva To Present New Phase III Data For Qnasl Nasal Aerosol At 2012 ACAAI Meeting
- Jul 26, 2012: Nuvo Research Receives €4.4m Additional Funding To Develop WF10
- May 01, 2012: Ista Reports Positive Phase II Trial Results Of BEPOSONE Nasal Spray
- Apr 27, 2012: Trimel Completes Treatment Phase Of CompleoTRT Allergic Rhinitis Special Population Study
- Apr 02, 2012: Actelion Provides Update On CRTH2 Program
- Mar 26, 2012: Teva Announces FDA Approval Of QNASL For Treatment Of Allergic Rhinitis
- Mar 05, 2012: Teva Reports Positive Results From Four Phase III Clinical Studies Of QNASL To Treat Allergic Rhinitis
- Jan 30, 2012: ISTA Completes Patient Enrollment In Phase II Clinical Study Of Beposone
- Jan 04, 2012: ISTA Pharmaceuticals Initiates Phase II Clinical Study Of BEPOSONE For Treatment Of Symptoms Associated With Seasonal Allergic Rhinitis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Seasonal Allergic Rhinitis, H2 2012
- Products under Development for Seasonal Allergic Rhinitis – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2012
- Johnson & Johnson, H2 2012
- Bausch & Lomb Incorporated, H2 2012
- Shionogi & Co., Ltd., H2 2012
- GlaxoSmithKline plc, H2 2012
- Merck & Co., Inc., H2 2012
- Dainippon Sumitomo Pharma Co., Ltd., H2 2012
- Novartis AG, H2 2012
- ALK-Abello A/S, H2 2012
- Mitsubishi Tanabe Pharma Corporation, H2 2012
- Teva Pharmaceutical Industries Limited, H2 2012
- Zeria Pharmaceutical Co Ltd, H2 2012
- Sun Pharmaceutical Industries Limited, H2 2012
- Capnia, Inc., H2 2012
- VentiRx Pharmaceuticals, Inc., H2 2012
- Adamis Pharmaceuticals Corporation, H2 2012
- Indigene Pharmaceuticals, Inc., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Seasonal Allergic Rhinitis Therapeutics – Drug Profile Updates
- Seasonal Allergic Rhinitis Therapeutics – Discontinued Products
- Seasonal Allergic Rhinitis Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Seasonal Allergic Rhinitis, H2 2012
- Products under Development for Seasonal Allergic Rhinitis – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractSeasonal Allergic Rhinitis – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Seasonal Allergic Rhinitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Seasonal Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seasonal Allergic Rhinitis. Seasonal Allergic Rhinitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Seasonal Allergic Rhinitis.
- A review of the Seasonal Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Seasonal Allergic Rhinitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Seasonal Allergic Rhinitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Seasonal Allergic Rhinitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
